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A B S T R A C T
Background
Vacuum and forceps assisted vaginal deliveries are reported to increase the incidence of postpartum infections and maternal readmission
to hospital compared to spontaneous vaginal delivery. Prophylactic antibiotics may be prescribed to prevent these infections. However,
the benefit of antibiotic prophylaxis for operative vaginal deliveries is still unclear.
Objectives
To assess the effectiveness and safety of antibiotic prophylaxis in reducing infectious puerperal morbidities in women undergoing
operative vaginal deliveries including vacuum or forceps deliveries, or both.
Search methods
We searched Cochrane Pregnancy and Childbirth’s Trials Register (12 July 2017), ClinicalTrials.gov, the WHO International Clinical
Trials Registry Platform (ICTRP) (12 July 2017) and reference lists of retrieved studies.
Selection criteria
All randomised trials comparing any prophylactic antibiotic regimens with placebo or no treatment in women undergoing vacuum or
forceps deliveries were eligible. Participants were all pregnant women without evidence of infections or other indications for antibiotics
of any gestational age undergoing vacuum or forceps delivery for any indications. Interventions were any antibiotic prophylaxis (any
dosage regimen, any route of administration or at any time during delivery or the puerperium) compared with either placebo or no
treatment.
Data collection and analysis
Two review authors assessed trial eligibility and methodological quality. Two review authors extracted the data independently using
prepared data extraction forms. Any discrepancies were resolved by discussion and a consensus reached through discussion with all
review authors. We assessed methodological quality of the one included trial using the GRADE approach.
Main results
One trial, involving 393 women undergoing either vacuum or forceps deliveries, was included. The trial compared the antibiotic
intravenous cefotetan after cord clamping compared with no treatment. This trial reported only two out of the nine outcomes specified
in this review. Seven women in the group given no antibiotics had endomyometritis and none in prophylactic antibiotic group, the risk
reduction was 93% (risk ratio (RR) 0.07; 95% confidence interval (CI) 0.00 to 1.21; low-quality evidence). There was no difference
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in the length of hospital stay between the two groups (mean difference (MD) 0.09 days; 95% CI -0.23 to 0.41; low-quality evidence).
Overall, the risk of bias was judged to be unclear. The quality of the evidence using GRADEwas low for both endometritis and maternal
length of stay.
Authors’ conclusions
One small trial was identified reporting only two outcomes. Evidence from this single trial suggests that antibiotic prophylaxis may
lead to little or no difference in endometritis or maternal length of stay. There were no data on any other outcomes to evaluate the
impact of antibiotic prophylaxis after operative vaginal delivery. Future research on antibiotic prophylaxis for operative vaginal delivery
is needed to conclude whether it is useful for reducing postpartum morbidity.
P L A I N L A N G U A G E S U M M A R Y
Is antibiotic prophylaxis effective or safe for women undergoing operative vaginal delivery?
What is the issue?
We wanted to assess whether giving antibiotics to all women undergoing operative vaginal deliveries (using vacuum suction or forceps)
prevents infections in the mother without increasing other adverse outcomes in the mother and baby.
Why is this important?
Women who undergo vacuum or forceps assisted vaginal births may be more likely to have an infection after the birth or be re-admitted
to hospital after the birth when compared to women who experience a normal spontaneous vaginal birth. The main reasons for an
operative vaginal delivery are a prolonged second stage of labour, suspicion of problems with the baby and a desire to shorten the second
stage of labour for maternal benefit.
Prophylactic antibiotics may be used to prevent or reduce the risk of these infections. However, there are still some doubts about the
benefit of prophylactic antibiotics in reducing postpartum infection after operative vaginal delivery.
What evidence did we find?
We searched for evidence in July 2017 and identified only one study published in 1989. The study included 393 women undergoing
either vacuum or forceps delivery comparing those receiving the antibiotic cefotetan with those women who received no treatment.
There were no differences between the two groups of women in terms of age, previous pregnancies and other important characteristics.
The only two outcomes reported in the trial were infection of the uterus (endometritis) and length of hospital stay. The trial reported
that seven women had an infection of the uterus (endometritis) in the group that did not receive any antibiotics. No woman in the
antibiotic group was reported to have an infection. Giving antibiotics had no effect on length of hospital stay for the mother for either
group. The quality of the evidence for these two outcomes was assessed as being low: the evidence comes from a single trial, which
included a very small number of women and reported on only two outcomes.
What does this mean?
Evidence from this single trial suggests that antibiotic prophylaxis may lead to little or no difference in endometritis or maternal length
of stay. There were no data on any other outcomes to evaluate the impact of antibiotics for preventing infection after operative vaginal
delivery. Future research on antibiotic prophylaxis for operative vaginal delivery is needed to provide evidence on whether it is a useful
intervention.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Any antibiotics versus placebo or no treatment for operative vaginal delivery
Population: women undergoing operat ive vaginal delivery
Settings: a hospital in USA
Intervention: any ant ibiot ics
Comparison: placebo or no treatment
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Control Any antibiotics versus
placebo or no treat-
ment
Endometritis Study population RR 0.07
(0 to 1.21)
393
(1 study)
⊕⊕©©
low1
35 per 1000 2 per 1000
(0 to 42)
M oderate
35 per 1000 2 per 1000
(0 to 42)
M aternal length of hos-
pital stay (days)
The mean maternal
length of stay in the in-
tervent ion groups was
0.09 higher
(0.23 lower to 0.41
higher)
393
(1 study)
⊕⊕©©
low1
Fever Not est imable 0 (no study) See comment This outcome was not
reported in the one in-
cluded study.3
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Infected episiotomy/
perineal/ vaginal lacer-
ation
Not est imable 0 (no study) See comment This outcome was not
reported in the one in-
cluded study.
Urinary tract infection Not est imable 0 (no study) See comment This outcome was not
reported in the one in-
cluded study.
Serious infectious
complications
Not est imable 0 (no study) See comment This outcome was not
reported in the one in-
cluded study.
M aternal adverse reac-
tions
Not est imable 0 (no study) See comment This outcome was not
reported in the one in-
cluded study.
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
CI: Conf idence interval; RR: Risk rat io;
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1 Wide conf idence interval crossing the line of no ef fect, few events and a small sample size.
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B A C K G R O U N D
Description of the condition
Operative vaginal delivery is the term used to describe delivery
of the fetal head assisted by either vacuum extractor or forceps.
The commonest indications for operative vaginal delivery are pro-
longed second stage of labour, suspicion of immediate or potential
fetal compromise and shortening of the second stage of labour
for maternal benefit (ACOG 2001). The rates of operative vagi-
nal delivery reported variously by centres in different countries
(Cammu 2011; Hanley 2010; Hehir 2013; Janni 2002; Kabiru
2001; Lawani 2014;Mola 2011;Walsh 2013) range from 2.1% in
Papua NewGuinea (Mola 2011) to 19.2% of all births in North-
ern Belgium (Cammu 2011).
The risk of postpartum infection is increased after operative vagi-
nal birth because of higher rates of vaginal lacerations, routine
bladder catheterisation, multiple vaginal examinations, insertion
of instruments into the vagina and contamination (Chaim 2000;
Pranchev 1993). Instrumental deliveries require additional vagi-
nal examinations, a known risk factor for endometritis and febrile
morbidity (Chang 1992;Dare 1998). Insertion of instruments and
contamination is also assumed to be one of the risks of postpartum
infection because of difficulties in adhering to aseptic practices
during delivery (Dare 1998).
Description of the intervention
Antibiotic prophylaxis is one of themethods used to reduce the risk
of postpartum infections. It has been widely studied in obstetrics
and has shown to be effective in reducing postoperative puerperal
morbidity after caesarean section in a Cochrane review (Smail
2014). However, there are still some doubts about the benefit of
prophylactic antibiotics in reducing postpartum infection after
operative vaginal delivery.
How the intervention might work
The reported incidence of postpartum infection or endometri-
tis after operative vaginal delivery varied from 3.5% to 16% (
Hagadorn-Freathy 1991;Heitmann 1989; Kabiru 2001;Williams
1991). In addition, the outcomes of readmission within 60 days
after delivery and maternal sepsis have been reported as increased
in incidence following the use of operative vaginal delivery in
comparison with spontaneous vaginal delivery (Acosta 2014; Liu
2005). Postpartum infection not only affects the physical status
of the mother and prolongs hospital stay after birth but also sig-
nificantly impacts on the psychological well-being of the mother
(ACOG 2001).
The most common micro-organisms in the genitourinary tract
causing postpartum morbidities such as fever, endometritis, in-
fected episiotomy/vaginal laceration or urinary tract infection are
Enterococci, Streptococci, Staphylococci, Gram-negative bacilli
and anaerobes (Kok 2000; Stray-Pedersen 1988). Group B strep-
tococcus, Enterococcus, Gardnerella vaginalis, Staphylococcus au-
reus and anaerobe bacteria were usually recovered from the cervix
and endometrium among febrile postpartumwomen (Eschenbach
1986).
Why it is important to do this review
Previous studies (Janisch 1979; Rechlin 1988) have indicated that
prophylactic antibiotics may not be necessary due to the relatively
low risk of infectious morbidity, and uncertain effect on puer-
peral fever. Aseptic precautions during operative vaginal delivery
may be enough to prevent postpartum infection (Janisch 1979).
In contrast, other studies did suggest that antibiotic prophylaxis
might reduce the risk of infection after normal vaginal delivery
and operative vaginal delivery (Fernandez 1993;Heitmann 1989).
Criscuolo 1990 suggested that the cost of prophylactic antibiotics
could be much lower compared with the cost of treating the com-
plications of infection related to procedures during delivery.
However, widespread use of antibiotics may contribute to
the development of antibiotic-resistant bacteria (Towers 1998;
Weinstein 1996). A study in Vietnam found that 98% of women
who gave birth vaginally received antibiotics (Ngoc 2005).
In addition, antibiotics may contaminate breast milk, as well as
cause adverse reactions such as rash or antibiotic-related diarrhoea
(Dancer 2004).
There is also a concern that there may be a significantly increased
risk of third or fourth degree tears, severe maternal morbidity and
death, perinatal mortality and neonatal mortality in women with
operative vaginal birth comparedwith normal birth (Angioli 2000;
Lumbiganon 2010). The incidence of third- and fourth-degree
tears reported range from 1% to 36% of all births (Boucoiran
2010;Goldberg 2003; Johnson 2004;Nkwabong 2011; Panigrahy
2008; Prapas 2009). The rate of perineal wound complication
measured at two weeks postpartum was found to be significantly
lower with the use of antibiotic prophylaxis; however, loss to fol-
low-up was high and thus these results should be interpreted with
caution (Buppasiri 2014; Duggal 2008).
Therefore, the effectiveness of antibiotic prophylaxis for operative
vaginal delivery needs to be carefully evaluated.
O B J E C T I V E S
To assess the effectiveness and safety of antibiotic prophylaxis in
reducing infectious puerperal morbidities in women undergoing
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operative vaginal deliveries including vacuum or forceps delivery,
or both.
M E T H O D S
Criteria for considering studies for this review
Types of studies
All randomised trials comparing any prophylactic antibiotic reg-
imens with placebo or no treatment in women undergoing vac-
uum or forceps deliveries. Cluster-trials were eligible for inclusion.
Quasi-randomised and cross-over trials were not eligible for inclu-
sion.
Types of participants
Pregnant women without evidence of infections or other indica-
tions for antibiotics of any gestational age undergoing vacuum or
forceps deliveries for any indications.
Types of interventions
Any antibiotic prophylaxis (any dosage regimen, any route of ad-
ministration or at any time during delivery or puerperium) com-
pared with either placebo or no treatment.
Types of outcome measures
We considered the following clinical outcomes.
Primary outcomes
1. Fever (body temperature of 38 degrees celsius or higher)
occurring on any two occasions in the first 10 days postpartum,
exclusive of the first 24 hours
2. Infected episiotomy/perineal/vaginal laceration
(oedematous, erythematous, wound edge with pain,
serosanguineous or frankly purulent material or wound
dehiscence)
3. Endometritis (fever and uterine tenderness or heavy
bleeding)
4. Urinary tract infection (fever or dysuria and positive urine
culture)
5. Serious infectious complications (such as bacteraemia,
septic shock, septic thrombophlebitis, necrotising fasciitis or
death attributed to infection)
Secondary outcomes
1. Maternal adverse reactions such as allergic reactions,
anaphylaxis, antibiotic-associated diarrhoea
2. Maternal length of stay
3. Costs
4. Neonatal adverse reactions such as such as jaundice, early
neonatal infection, or any infant outcomes reported
Search methods for identification of studies
The following methods section of this review was based on a stan-
dard template used by Cochrane Pregnancy and Childbirth.
Electronic searches
We searched Cochrane Pregnancy and Childbirth’s Trials Register
by contacting their Information Specialist (12 July 2017).
The Register is a database containing over 23,000 reports of con-
trolled trials in the field of pregnancy and childbirth. For full search
methods used to populate Pregnancy andChildbirth’s Trials Regis-
ter including the detailed search strategies for CENTRAL, MED-
LINE, Embase and CINAHL; the list of handsearched journals
and conference proceedings, and the list of journals reviewed via
the current awareness service, please follow this link to the edi-
torial information about the Cochrane Pregnancy and Childbirth
in the Cochrane Library and select the ‘Specialized Register ’ sec-
tion from the options on the left side of the screen.
Briefly, the Cochrane Pregnancy and Childbirth’s Trials Register
is maintained by their Information Specialist and contains trials
identified from:
1. monthly searches of the Cochrane Central Register of
Controlled Trials (CENTRAL);
2. weekly searches of MEDLINE (Ovid);
3. weekly searches of Embase (Ovid);
4. monthly searches of CINAHL (EBSCO);
5. handsearches of 30 journals and the proceedings of major
conferences;
6. weekly current awareness alerts for a further 44 journals
plus monthly BioMed Central email alerts.
Search results are screened by two people and the full text of all
relevant trial reports identified through the searching activities de-
scribed above is reviewed. Based on the intervention described,
each trial report is assigned a number that corresponds to a spe-
cific Pregnancy and Childbirth review topic (or topics), and is
then added to the Register. The Information Specialist searches the
Register for each review using this topic number rather than key-
words. This results in a more specific search set that has been fully
accounted for in the relevant review sections (Included studies;
Excluded studies; Ongoing studies).
In addition, we searched ClinicalTrials.gov and the WHO Inter-
national Clinical Trials Registry Platform (ICTRP) for unpub-
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lished, planned and ongoing trial reports (12 July 2017) using the
search terms given in Appendix 1.
Searching other resources
We searched the reference lists of retrieved studies.
We did not apply any language or date restrictions.
Data collection and analysis
For methods used in the previous version of this review, see
Liabsuetrakul 2014b.
For this update, we planned to use the following methods. One
new ongoing study was identified (ANODE 2015) and we will
review it in the next update.
The followingmethods section of this review is based on a standard
template used by Cochrane Pregnancy and Childbirth.
Selection of studies
Two review authors independently assessed for inclusion all the
potential studies identified as a result of the search strategy. We
resolved any disagreement through discussion or, if required, we
consulted the third review author.
Data extraction and management
We designed a form to extract data. For eligible studies, two re-
view authors extracted the data using the agreed form.We resolved
discrepancies through discussion or, if required, we consulted the
third review author. Data were entered into Review Manager soft-
ware (RevMan 2014) and checked for accuracy.
When information regarding any of the above was unclear, we
planned to contact authors of the original reports to provide fur-
ther details.
Assessment of risk of bias in included studies
Two review authors independently assessed risk of bias for each
study using the criteria outlined in theCochrane Handbook for Sys-
tematic Reviews of Interventions (Higgins 2011). Any disagreement
was resolved by discussion or by involving a third assessor.
(1) Random sequence generation (checking for possible
selection bias)
We described for the one included study the method used to gen-
erate the allocation sequence in sufficient detail to allow an assess-
ment of whether it should produce comparable groups.
We assessed the method as:
• low risk of bias (any truly random process, e.g. random
number table; computer random number generator);
• high risk of bias (any non-random process, e.g. odd or even
date of birth; hospital or clinic record number);
• unclear risk of bias.
(2) Allocation concealment (checking for possible selection
bias)
Wedescribed for the included study themethod used to conceal al-
location to interventions prior to assignment and assessed whether
intervention allocation could have been foreseen in advance of, or
during recruitment, or changed after assignment.
We assessed the methods as:
• low risk of bias (e.g. telephone or central randomisation;
consecutively numbered sealed opaque envelopes);
• high risk of bias (open random allocation; unsealed or non-
opaque envelopes, alternation; date of birth);
• unclear risk of bias.
(3.1) Blinding of participants and personnel (checking for
possible performance bias)
We described for the one included study the methods used, if
any, to blind study participants and personnel from knowledge
of which intervention a participant received. We considered in
advance that studies would be at low risk of bias if they were
blinded, or if we judged that the lack of blinding unlikely to affect
results. We assessed blinding separately for different outcomes or
classes of outcomes.
We assessed the methods as:
• low, high or unclear risk of bias for participants;
• low, high or unclear risk of bias for personnel.
(3.2) Blinding of outcome assessment (checking for possible
detection bias)
We described for the included study the methods used, if any, to
blind outcome assessors from knowledge of which intervention a
participant received. We assessed blinding separately for different
outcomes or classes of outcomes.
We assessed methods used to blind outcome assessment as:
• low, high or unclear risk of bias.
(4) Incomplete outcome data (checking for possible attrition
bias due to the amount, nature and handling of incomplete
outcome data)
We described for the included study, and for each outcome or class
of outcomes, the completeness of data including attrition and ex-
clusions from the analysis. We stated whether attrition and exclu-
sions were reported and the numbers included in the analysis at
each stage (compared with the total randomised participants), rea-
sons for attrition or exclusion where reported, and whether miss-
ing data were balanced across groups or were related to outcomes.
Where sufficient information was reported, or could be supplied
by the trial authors, we planned to re-include missing data in the
analyses which we undertook.
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We assessed methods as:
• low risk of bias (e.g. no missing outcome data; missing
outcome data balanced across groups);
• high risk of bias (e.g. numbers or reasons for missing data
imbalanced across groups; ‘as treated’ analysis done with
substantial departure of intervention received from that assigned
at randomisation);
• unclear risk of bias.
(5) Selective reporting (checking for reporting bias)
We described for the included study how we investigated the pos-
sibility of selective outcome reporting bias and what we found.
We assessed the methods as:
• low risk of bias (where it is clear that all of the study’s pre-
specified outcomes and all expected outcomes of interest to the
review have been reported);
• high risk of bias (where not all the study’s pre-specified
outcomes have been reported; one or more reported primary
outcomes were not pre-specified; outcomes of interest are
reported incompletely and so cannot be used; study fails to
include results of a key outcome that would have been expected
to have been reported);
• unclear risk of bias.
(6) Other bias (checking for bias due to problems not
covered by (1) to (5) above)
We described for the one included study any important concerns
we had about other possible sources of bias.
(7) Overall risk of bias
We made explicit judgements about whether the included study
was at high risk of bias, according to the criteria given in the
Handbook (Higgins 2011). With reference to (1) to (6) above, we
planned to assess the likely magnitude and direction of the bias
and whether we considered it is likely to impact on the findings.
In future updates, if more studies are included, we will explore the
impact of the level of bias through undertaking sensitivity analyses
- see Sensitivity analysis.
Assessment of the quality of the evidence using the
GRADE approach
We assessed the quality of the evidence using the GRADE ap-
proach as outlined in the GRADE handbook in order to assess the
quality of the body of evidence relating to the following outcomes
for the main comparison between any antibiotic prophylaxis (any
dosage regimen, any route of administration or at any time dur-
ing delivery or puerperium) compared with either placebo or no
treatment.
1. Fever (body temperature of 38 degrees celsius or higher)
occurring on any two occasions in the first 10 days postpartum,
exclusive of the first 24 hours
2. Infected episiotomy/perineal/vaginal laceration
(oedematous, erythematous, wound edge with pain,
serosanguineous or frankly purulent material or wound
dehiscence)
3. Endometritis (fever and uterine tenderness or heavy
bleeding)
4. Urinary tract infection (fever or dysuria and positive urine
culture)
5. Serious infectious complications (such as bacteraemia,
septic shock, septic thrombophlebitis, necrotising fasciitis or
death attributed to infection)
6. Maternal adverse reactions such as allergic reactions,
anaphylaxis, antibiotic-associated diarrhoea
7. Maternal length of stay
We used the GRADEpro Guideline Development Tool to import
data from Review Manager 5.3 (RevMan 2014) in order to create
a ’Summary of findings’ table. A summary of the intervention
effect and a measure of quality for each of the above outcomes was
produced using the GRADE approach. The GRADE approach
uses five considerations (study limitations, consistency of effect,
imprecision, indirectness and publication bias) to assess the quality
of the body of evidence for each outcome. The evidence can be
downgraded from ’high quality’ by one level for serious (or by
two levels for very serious) limitations, depending on assessments
for risk of bias, indirectness of evidence, serious inconsistency,
imprecision of effect estimates or potential publication bias.
Measures of treatment effect
Dichotomous data
For dichotomous data, we presented results as summary risk ratio
with 95% confidence intervals.
Continuous data
Weplanned to use themean difference if outcomes weremeasured
in the same way between trials.We planned to use the standardised
mean difference to combine trials that measured the same out-
come, but used different methods. As only one trial, was included,
we used the mean difference.
Unit of analysis issues
Cluster-randomised trials
In future updates, if cluster-randomised trials are identified and
included, we will adjust the sample errors using the methods de-
scribed in the Handbook using an estimate of the intracluster cor-
relation co-efficient (ICC) derived from the trial (if possible), from
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a similar trial or from a study of a similar population. If we use
ICCs from other sources, we will report this and conduct sensi-
tivity analyses to investigate the effect of variation in the ICC.
If we identify both cluster-randomised trials and individually-ran-
domised trials, we plan to synthesise the relevant information.
We will consider it reasonable to combine the results from both
if there is little heterogeneity between the study designs and the
interaction between the effect of intervention and the choice of
randomisation unit is considered to be unlikely.
We will also acknowledge heterogeneity in the randomisation unit
and perform a sensitivity analysis to investigate the effects of the
randomisation unit.
Cross-over trials
Not applicable.
Other unit of analysis issues
Not applicable.
Dealing with missing data
For included studies, we noted levels of attrition. In future up-
dates, if more eligible studies are included, the impact of including
studies with high levels of missing data in the overall assessment
of treatment effect will be explored by using sensitivity analysis.
For all outcomes, analyses were carried out, as far as possible, on
an intention-to-treat basis, i.e. we attempted to include all par-
ticipants randomised to each group in the analyses. The denom-
inator for each outcome in the included study was the number
randomised minus any participants whose outcomes were known
to be missing.
Assessment of heterogeneity
There was only one included study and so it was not necessary
to assess heterogeneity. In future updates, we will assess statistical
heterogeneity in each meta-analysis using the Tau², I² and Chi²
statistics. We will regard heterogeneity as substantial if an I² is
greater than 30% and either a Tau² is greater than zero, or there is
a low P value (less than 0.10) in the Chi² test for heterogeneity. If
we identify substantial heterogeneity (above 30%), we will explore
it by pre-specified subgroup analysis.
Assessment of reporting biases
In future updates, if there are 10 or more studies in the meta-
analysis we will investigate reporting biases (such as publication
bias) using funnel plots. We will assess funnel plot asymmetry
visually. If asymmetry is suggested by a visual assessment, we will
perform exploratory analyses to investigate it.
Data synthesis
We carried out statistical analysis using the Review Manager soft-
ware (RevMan 2014). Only one study was included. In future
updates, if more trials become available for inclusion, we will use
fixed-effectmeta-analysis for combining datawhere it is reasonable
to assume that studies are estimating the same underlying treat-
ment effect: i.e. where trials are examining the same intervention,
and the trials’ populations and methods are judged sufficiently
similar.
If there is clinical heterogeneity sufficient to expect that the under-
lying treatment effects differ between trials, or if substantial statis-
tical heterogeneity is detected, we will use random-effects meta-
analysis to produce an overall summary, if an average treatment ef-
fect across trials is considered clinically meaningful. The random-
effects summary will be treated as the average range of possible
treatment effects and we will discuss the clinical implications of
treatment effects differing between trials. If the average treatment
effect is not clinically meaningful, we will not combine trials. If
we use random-effects analyses, the results will be presented as the
average treatment effect with 95% confidence intervals, and the
estimates of Tau² and I².
Subgroup analysis and investigation of heterogeneity
Only one trial was included and so it was not necessary to carry out
subgroup analysis. In future updates if more studies are included
and we identify substantial heterogeneity, we plan to investigate it
using subgroup analyses and we will consider whether an overall
summary is meaningful, and if it is, we will use a random-effects
analysis to produce it.
In future updates, we will carry out the following subgroup anal-
yses for primary outcomes.
1. Vacuum or forceps deliveries
2. Different antibiotic regimens
We will assess subgroup differences by interaction tests available
within RevMan (RevMan 2014). We will report the results of
subgroup analyses quoting the Chi² statistic and P value, and the
interaction test I² value.
Sensitivity analysis
We planned to carry out sensitivity analyses to explore the effect of
trial quality assessed by concealment of allocation, high attrition
rates, or both, with poor quality studies being excluded from the
analyses in order to assess whether this makes any difference to the
overall result. As only one study was included, we were unable to
carry out the planned sensitivity analysis.
R E S U L T S
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Description of studies
Results of the search
See: Figure 1.
Figure 1. Study flow diagram.
The original search of the Cochrane Pregnancy and Childbirth
Group’s Trials Register retrieved three trial reports, one trial was
included and one trial (two reports) was excluded. An updated
search in July 2017 retrieved no further reports from the Preg-
nancy and Childbirth Group’s Trials Register and nine reports
from ClinicalTrials.gov and the WHO International Clinical Tri-
als Registry Platform (ICTRP). Eight of these were screened out
as not within the scope of the review and one study was added to
Ongoing studies.
One ongoing trial ANODE 2015 met the inclusion criteria and
was added to Ongoing studies. This trial was started in Septem-
ber 2009 and includes healthy women aged over 16 years hav-
ing an operative vaginal delivery. The comparison is between a
single intravenous dose of co-amoxiclav (1 g amoxycillin/200 mg
clavulanic acid in 20 mL water for injections for active drug) and
placebo (20 mL 0.9% saline for placebo). The main outcome is
confirmed or suspected maternal infection within six weeks of de-
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livery. The trial is expected to finish in August 2017.
Included studies
For details of the one included trial, see the Characteristics of
included studies table.
Heitmann 1989 met the inclusion criteria. The trial was carried
out between September 1986 and February 1989, involving 393
women undergoing either vacuum or forceps delivery. The com-
parison was between 2 g of cefotetan (n = 192) versus no treatment
(n = 201). The randomisation procedure and outcome assessment
were not described in the trial report. Nevertheless, there were no
differences between the two groups regarding age, parity, fourth-
degree laceration, length of first and second stage of labour, dura-
tion of ruptured membrane, number of documented vaginal ex-
aminations, total time in labour and delivery suite, type of mon-
itoring used, type of anaesthesia or level of physician’s expertise.
The main outcome was endomyometritis. The funding sources
of were not described and no declarations of interest among the
primary researchers were reported.
Excluded studies
One trial was excluded (DeMeeus 1991). The trial was only avail-
able as an abstract and there was insufficient information in order
to assess fully for eligibility. We have contacted the authors for
further information. For further details of the excluded study, see
the Characteristics of excluded studies table.
Risk of bias in included studies
Details of the one included trial are in the Characteristics of
included studies table. Each risk of bias domain in summarised in
Figure 2 and Figure 3.
Figure 2. ’Risk of bias’ graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 3. ’Risk of bias’ summary: review authors’ judgements about each risk of bias item for each included
study.
Allocation
Heitmann 1989 used a randomisation table to generate allocation
sequence, but did not report concealment of randomisation. There
were more vacuum deliveries than forceps deliveries but they were
equally balanced between the two groups (vacuum rate was 57%
in the cefotetan group and 59% in the no treatment group).
Blinding
There were no details of the blinding of intervention to either
women or clinicians as well as the outcomemeasurements. It could
be assumed that it was not blinded because the comparison was no
treatment. However, the main outcome was objectively measured
so it was unlikely to have been influenced by lack of blinding.
Incomplete outcome data
The number of samples given at interventionwas the same as those
at outcome measure; however, the intention-to-treat analysis was
not clearly described.
Selective reporting
The study protocol was not available; therefore, there was insuffi-
cient information to permit judgement. There was no attempt to
analyse the subgroups according to the type of delivery.
Other potential sources of bias
The study appeared to be free of other sources of bias.
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Effects of interventions
See: Summary of findings for the main comparison Any
antibiotics versus placebo or no treatment for operative vaginal
delivery
One trial was included in the review comparing cefotetan given
after cord clamping with no treatment group (Heitmann 1989).
This trial recruited 393 women and reported only two out of the
nine outcomes specified in this review (endometritis for primary
outcome and maternal length of stay for secondary outcome).
There were no cases of endomyometritis in the cefotetan group
compared with sevenwomen (4%) in the no treatment group. The
risk reduction was 93% (risk ratio (RR) 0.07; 95% confidence
interval (CI) 0.00 to 1.21; low-quality evidence) (Analysis 1.1).
There was no difference in the length of hospital stay between
the two groups in days (mean difference (MD) 0.09; 95% CI -
0.23 to 0.41; low-quality evidence) (Analysis 1.2). Both outcomes
were assessed as being of low quality according to GRADE. The
reasons for downgrading the quality of the evidence were because
of a wide confidence interval crossing the line of no effect, few
events and small sample size.
D I S C U S S I O N
Summary of main results
One trial, involving 393 women undergoing either vacuum or
forceps deliveries, was included. The trial compared the antibi-
otic intravenous cefotetan after cord clamping compared with no
treatment. This trial reported only two out of the nine outcomes
specified in this review. Seven women in the group given no an-
tibiotics had endomyometritis and none in prophylactic antibiotic
group, the risk reduction was 93%. There was no difference in the
length of hospital stay between the two groups.
Overall completeness and applicability of
evidence
Only one small study reporting on only two outcomes with few
events was identified for inclusion in this review included. This
is a major limitation of this review. The results of this systematic
review should therefore be interpreted with caution.
Quality of the evidence
Overall, the included study was at low risk of bias except for allo-
cation concealment, blinding and selective reporting, the details
for which were unclear. We could not assess fever, infected epi-
siotomy/perineal/vaginal laceration, urinary tract infection, seri-
ous infectious complications and maternal adverse reactions be-
cause these outcomes were not reported in the trial. Therefore, we
assessed endometritis and maternal length of stay in hospital. The
quality of the evidence using GRADE was low for endometritis,
andmaternal length of stay in hospital. The reasons for downgrad-
ing the quality of the evidence were because of a wide confidence
interval crossing the line of no effect, few events and small sample
size.
Potential biases in the review process
We conducted an extensive search, but it remains possible that
studies may have been missed. If we identify any such studies in
future searches, we will assess them for potential inclusion in this
review.
As the quality of the included trial is unclear, the potential for bias
is present. Another significant source of potential bias is missing
outcome data. Therefore study results should be interpreted with
caution.
Agreements and disagreements with other
studies or reviews
There are no other systematic reviews on antibiotic prophylaxis for
operative vaginal delivery published. No additional randomised
controlled trials on this issue have been conducted. Although there
was no evidence to support the use of antibiotic prophylaxis in
operative vaginal delivery, it is widely used in clinical practice
(Liabsuetrakul 2014a).
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
One small trial was identified reporting only two outcomes. Evi-
dence from this single trial suggests that antibiotic prophylaxismay
lead to little or no difference in endometritis or maternal length
of stay. There were no data on any other outcomes to evaluate the
impact of antibiotic prophylaxis after operative vaginal delivery.
Implications for research
Future research on antibiotic prophylaxis for operative vaginal de-
livery is needed to clarify whether this intervention is effective in
reducing postpartum morbidity, particularly because it is widely
used in current practice. Biases should be reduced by appropriate
methods of allocation concealment, blinded interventions, clearly
defined outcomes and consistent outcome measures. The drug
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regimens for future trials should be based on the principle of an-
tibiotic prophylaxis for caesarean section with a single dose of in-
travenous ampicillin or first-generation cephalosporins after cord
clamping.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Heitmann 1989
Methods Selected by randomisation table to receive treatment or no treatment; not blinded or
placebo-controlled
Participants 393 women undergoing instrumental deliveries (either vacuum or forceps deliveries).
Women were excluded if they had evidence of chorioamnionitis, or other infections, or
if they were allergic to penicillin or cephalosporins.
Setting: University Hospital of Jacksonville, USA; September 1986 to February 1988
Interventions 2 g of cefotetan intravenously after cord clamping (n = 192) or no treatment (n = 201)
Outcomes Endomyometritis (at least 1 rise in oral temperature greater than 38.1 degrees Celsius
after the first 24 hours of delivery and uterine tenderness or foul-smelling lochia with
no clinical or laboratory evidence confirming another source of the fever)
Notes Dates study conducted: the trial was carried out between September 1986 and February
1989
Funding sources for the study: the funding sources of an included study could not be
identified
Declarations of interest among primary researchers: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk A randomisation table was used for random
sequence generation
Allocation concealment (selection bias) Unclear risk Allocation concealment could not be inter-
preted.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Information not clearly mentioned.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Who measured the outcome was not men-
tioned.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Same number of samples at intervention
given and outcome measure
Selective reporting (reporting bias) Unclear risk The study protocol was not available, so
there was insufficient information to per-
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Heitmann 1989 (Continued)
mit judgement
Other bias Low risk Study appeared to be free of other sources
of bias.
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
De Meeus 1991 Abstract only (translated). This randomised study included 200 women including, not only instrumental delivery
but also women undergoing manual removal of placenta or uterine exploration, or both, premature rupture of the
membranes of more than 6 hours and a labour of more than 8 hours. No details of the interventions were given for
either the treatment or the control groups. The study outcomes of postpartum fever in both comparison groups
were given but they were not described for subgroups; therefore, there were no data suitable for extraction. We
could not find a published article. We have tried to contact the author but without success to date
Characteristics of ongoing studies [ordered by study ID]
ANODE 2015
Trial name or title ANODE: Prophylactic antibiotics for the prevention of infection following operative delivery
Methods Participants are randomly allocated into two groups.
Participants Healthy women aged 16 years and over who have had an operative vaginal delivery
Interventions Co-amoxiclav versus placebo, A single intravenous dose (1 g amoxycillin/200 mg clavulanic acid in 20 mL
water for injections for active drug, 20 mL 0.9% saline for placebo)
Outcomes Confirmed or suspected maternal infection within 6 weeks of delivery
Starting date September 2009.
Contact information Mrs Shan Gray. NPEU Clinical Trials Unit, Oxford (UK)
Notes Expected to finish in August 2017.
EudraCT number: 2015-000872-89.
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D A T A A N D A N A L Y S E S
Comparison 1. Any antibiotics versus placebo or no treatment
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Endometritis 1 393 Risk Ratio (M-H, Fixed, 95% CI) 0.07 [0.00, 1.21]
2 Maternal length of stay 1 393 Mean Difference (IV, Fixed, 95% CI) 0.09 [-0.23, 0.41]
Analysis 1.1. Comparison 1 Any antibiotics versus placebo or no treatment, Outcome 1 Endometritis.
Review: Antibiotic prophylaxis for operative vaginal delivery
Comparison: 1 Any antibiotics versus placebo or no treatment
Outcome: 1 Endometritis
Study or subgroup Any antibiotics No treatment Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Heitmann 1989 0/192 7/201 100.0 % 0.07 [ 0.00, 1.21 ]
Total (95% CI) 192 201 100.0 % 0.07 [ 0.00, 1.21 ]
Total events: 0 (Any antibiotics), 7 (No treatment)
Heterogeneity: not applicable
Test for overall effect: Z = 1.83 (P = 0.068)
Test for subgroup differences: Not applicable
0.005 0.1 1 10 200
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Analysis 1.2. Comparison 1 Any antibiotics versus placebo or no treatment, Outcome 2 Maternal length of
stay.
Review: Antibiotic prophylaxis for operative vaginal delivery
Comparison: 1 Any antibiotics versus placebo or no treatment
Outcome: 2 Maternal length of stay
Study or subgroup Any antibiotics No treatment
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Heitmann 1989 192 2.46 (1.44) 201 2.37 (1.8) 100.0 % 0.09 [ -0.23, 0.41 ]
Total (95% CI) 192 201 100.0 % 0.09 [ -0.23, 0.41 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.55 (P = 0.58)
Test for subgroup differences: Not applicable
-2 -1 0 1 2
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A P P E N D I C E S
Appendix 1. Search terms for ClinicalTrials.gov and ICTRP
Searched 12 July 2017
(vacuum OR forceps OR ventouse) AND antibiotics AND (labour OR labor OR birth OR delivery)
(Search was broken down into separate lines).
WH A T ’ S N E W
Last assessed as up-to-date: 12 July 2017.
Date Event Description
12 July 2017 New citation required but conclusions have not changed Conclusions remain unchanged.
12 July 2017 New search has been performed Search updated and one new ongoing study identified
(ANODE 2015).
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H I S T O R Y
Protocol first published: Issue 4, 2003
Review first published: Issue 3, 2004
Date Event Description
31 August 2014 New citation required but conclusions have not
changed
Reviewupdated.Nonew trials identified so conclusions
remain unchanged
31 August 2014 New search has been performed Search updated, no further trials identified. Methods
updated. Please note that blinding has now been di-
vided into two assessments: 1. Blinding of participants
and personnel (performance bias); and 2. Blinding of
outcome assessors (detection bias). Tables have been up-
dated. A ’Summary of findings’ table has been incorpo-
rated for this update
12 October 2012 Amended The Acknowledgements section has been edited.
18 July 2012 New citation required but conclusions have not
changed
No new trials identified.
18 July 2012 New search has been performed New search for trials conducted and Background up-
dated.
31 August 2008 New search has been performed Search updated. No new studies identified.
3 April 2008 Amended Converted to new review format.
30 June 2007 New search has been performed Search updated. No new trials identified.
31 August 2005 New search has been performed Search updated. No new trials identified.
3 April 2004 Amended Substantive amendment.
C O N T R I B U T I O N S O F A U T H O R S
Tippawan Liabsuetrakul (TL) gathered background information and wrote the first and final draft of the protocol. TL assessed trial
eligibility and methodological quality, extracted data, wrote the first draft of the review and co-ordinated the comments from the other
review authors. For the 2008 update, TL reviewed the draft and final version of the updated review. For the 2012, 2014 and the current
2017 update, TL reviewed and updated the text.
Thanapan Choobun (TC) gathered background information and commented on the draft protocol. TC assessed trial eligibility and
methodological quality, extracted data and commented on the draft review. For the 2008 update, TC approved the final version of the
updated review. For the 2012, 2014 and the current 2017 update, TC approved the version for publication.
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Krantarat Peeyananjarassri (KP) gathered background information and commented on the draft protocol. KP commented on the draft
review. For the 2008 update, KP approved the final version of the updated review. For the 2012, 2014 and the current 2017 update,
KP approved the version for publication.
Monir Islam (MI) supervised the development of the protocol and review. MI commented on the draft protocol and review. For the
2008 update, MI approved the final version of the updated review. For the 2012, 2014 and the current 2017 update, MI approved the
version for publication.
D E C L A R A T I O N S O F I N T E R E S T
Tippawan Liabsuetrakul: none known.
Thanapan Choobun: none known.
Krantarat Peeyananjarassri: none known.
Q Monir Islam: none known.
S O U R C E S O F S U P P O R T
Internal sources
• Faculty of Medicine, Prince of Songkla University, Thailand.
External sources
• Thailand Research Fund (Distinguished Research Professor Award), Thailand.
• UNDP-UNFPA-UNICEF-WHO-World Bank Special Programme of Research, Development and Research Training in Human
Reproduction (HRP), Department of Reproductive Health and Research (RHR), World Health Organization, Switzerland.
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
Methods updated to current standard PCG methods (2017).
We added in an additional search of ClinicalTrials.gov and the WHO International Clinical Trials Registry Platform (ICTRP).
I N D E X T E R M S
Medical Subject Headings (MeSH)
∗Antibiotic Prophylaxis; Endometritis [prevention & control]; Extraction, Obstetrical [∗adverse effects]; Obstetrical Forceps; Puerperal
Infection [∗prevention & control]; Randomized Controlled Trials as Topic; Vacuum Extraction, Obstetrical [adverse effects]; Vaginal
Diseases [∗prevention & control]
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MeSH check words
Female; Humans; Pregnancy
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